modipafant
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT02569827)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Platelet activating factor receptorANTAGONIST
PTAFR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)C1=C(c2ccc(-n3c(C)nc4cnccc43)cc2)NC(C)=C(C(=O)Nc2ccccn2)[C@H]1c1ccccc1Cl- Mol. weight
- 605.1 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105829 ↗
Also known as
- 3-pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(4-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)-5-((2-pyridinylamino)carbonyl)-, ethyl ester
- 4-(2-chlorophenyl)-6-methyl-2-(4-(2-methylimidazo(4,5-c)pyrid-1-yl)phenyl)-5-(2-pyridinylcarbamoyl)-1,4-dihydropyridine-3-carboxylic acid ethyl ester
- modipafant
- modipafant
- modipafant
- modipafant
- uk 74505
- uk-74505
- uk 80067
- uk-80067
- uk-80067
- uk-80067
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02569827 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | 60 Degrees Pharmaceuticals LLC, Duke University, Singapore General Hospital |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals LLC | For profit | 1 | 0 | 1 | 2017 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Singapore General Hospital | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1